Targets › HPV
9 programs from 7 companies in 10 trials: 5 Phase 2, 3 Phase 3, 2 Phase 4; Oncology, Infectious disease, Vaccines; next expected readout Mar 2027.
Open in Phaseline: the race on HPV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Karolinska Institutet | Gardasil 9 Nonavalent human papillomavirus (HPV) vaccine | HPV | Phase 4 | Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection | Dec 2027 |
| Miriam Elfström | Gardasil9 Recombinant HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, 58) | HPV | Phase 4 | HPV Infection | Dec 2027 |
| London School of Hygiene and Tropical Medicine | bivalent HPV vaccine bivalent HPV vaccine targeting HPV types 16 and 18 | HPV | Phase 3 | Human Papilloma Virus | Mar 2027 |
| London School of Hygiene and Tropical Medicine | nonavalent HPV vaccine nonavalent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 | HPV | Phase 3 | Human Papilloma Virus | Mar 2027 |
| National Vaccine and Serum Institute, China | 11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha) Recombinant HPV vaccine covering 11 HPV types | HPV | Phase 3 | HPV InfectioN | Jun 2028 |
| International Vaccine Institute | OSP:rTTHc Cholera Conjugate Vaccine (CCV) Bivalent HPV vaccine | HPV | Phase 2 | Cholera Vaccination; HPV Vaccine | Mar 2027 |
| Michael K. Gibson | TA-HPV Human papillomavirus tumor antigen vaccine | HPV | Phase 2 | Metastatic Oropharyngeal Carcinoma | Sep 2027 |
| Michael K. Gibson | pBI-11 DNA plasmid vaccine encoding HPV antigens that promotes antibody, cytotoxic T cell, and pr | HPV | Phase 2 | Metastatic Oropharyngeal Carcinoma | Sep 2027 |
| Centre Oscar Lambret | Human Papillomavirus 9-valent Vaccine, Recombinant 9-valent HPV vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 | HPV | Phase 2 | Cervical Lesion | Oct 2028 |
Metastatic Oropharyngeal Carcinoma (2) Human Papilloma Virus (2) Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection (1) Cervical Lesion (1) Cholera Vaccination (1) HPV Vaccine (1) HPV Infection (1) HPV InfectioN (1)
other (4), protein or peptide (3), mixed (2)
Michael K. Gibson (2) London School of Hygiene and Tropical Medicine (2) Karolinska Institutet (1) Centre Oscar Lambret (1) International Vaccine Institute (1) Miriam Elfström (1) National Vaccine and Serum Institute, China (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.